These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2886066)

  • 1. Depot neuroleptics for acutely psychotic patients.
    Turns DM; Pary R; Tobias CR; James WA
    Am J Psychiatry; 1987 Aug; 144(8):1099-100. PubMed ID: 2886066
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
    Ereshefsky L; Saklad SR; Jann MW; Davis CM; Richards A; Seidel DR
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):50-9. PubMed ID: 6143748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
    Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
    Moore DB; Kelly DL; Sherr JD; Love RC; Conley RR
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S17-9. PubMed ID: 9872689
    [No Abstract]   [Full Text] [Related]  

  • 10. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
    Marchant N; Caruso S; Cuervo L; Brizuela A
    Acta Psiquiatr Psicol Am Lat; 1985 Mar; 31(1):37-41. PubMed ID: 2864788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the efficacy of haloperidol decanoate].
    Alvarez JV; Li Gambi M
    Acta Psiquiatr Psicol Am Lat; 1986 Sep; 32(3):233-6. PubMed ID: 2884807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.
    Stuyt EB; Sajbel TA; Allen MH
    Am J Addict; 2006; 15(2):166-73. PubMed ID: 16595355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.
    Kucharski LT; Alexander P; Tune L; Coyle J
    Psychopharmacology (Berl); 1984; 82(3):194-8. PubMed ID: 6144127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and mechanism of action of existing and new neuroleptics.
    Niemegeers CJ
    Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):26-36. PubMed ID: 1981439
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of prolonged-action neuroleptics on rehospitalization of psychotic patients in a regional practice].
    Richou H
    Ann Med Psychol (Paris); 1975 Jul; 2(2):399-402. PubMed ID: 9894
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
    De Cuyper H; Bollen J; van Praag HM; Verstraeten D
    Br J Psychiatry; 1986 May; 148():560-6. PubMed ID: 2877701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.